Form 4: Atai Beckley Director Granted Options Post-Acquisition

Atai Beckley N.V. director Robert Hershberg was granted stock options following the acquisition of Beckley Psytech Limited.

Summary

• Robert Hershberg, a director of Atai Beckley N.V., received stock options as reported in this Form 4 filing.
• The options are connected to Atai Beckley N.V.'s acquisition of the entire issued share capital of Beckley Psytech Limited, which was completed on November 5, 2025.
• Atai Beckley acquired all outstanding equity interests of Beckley Psytech in exchange for an aggregate of 103,000,066 common shares of the Issuer, issued directly as share consideration or as underlying replacement awards.
• Hershberg was granted stock options for 456,011, 97,716, and 62,394 common shares, each with an exercise price of $1.35, which are fully vested as of the grant date.
• Additionally, Hershberg received stock options for 103,000 common shares with an exercise price of $4.48, which are scheduled to vest in full on the first anniversary of the grant date.

Sentiment

Score: 6

Explanation: The filing is primarily a factual report of an insider transaction following an acquisition. The completion of the acquisition and the grant of options to a director are generally neutral to mildly positive events, indicating operational progress and potential alignment of interests, but do not provide performance metrics.

Positives

• The completion of the acquisition of Beckley Psytech Limited by Atai Beckley N.V. signifies potential strategic growth and expansion.
• The grant of stock options to a director, Robert Hershberg, can align management's interests with those of shareholders, incentivizing long-term performance.

Future Outlook

One tranche of stock options for 103,000 common shares, granted to Robert Hershberg, is scheduled to vest in full on the first anniversary of the grant date (November 5, 2025). The completion of the Beckley Psytech acquisition suggests a strategic move to integrate its operations and pipeline into Atai Beckley's future plans.

Industry Context

This filing reflects an ongoing trend of consolidation and strategic acquisitions within the biotechnology and pharmaceutical sectors, particularly in emerging areas like psychedelic-assisted therapies, where Atai Beckley N.V. operates. The acquisition of Beckley Psytech Limited could enhance Atai Beckley's research and development capabilities or expand its intellectual property portfolio in this specialized field.

Stakeholder Impact

• Shareholders: The issuance of 103,000,066 common shares for the acquisition of Beckley Psytech Limited will result in dilution of existing shareholdings. The grant of stock options to a director may align his interests with long-term shareholder value.
• Employees: Employees of Beckley Psytech Limited are now part of Atai Beckley N.V. following the acquisition.

Next Steps

• The 103,000 stock options granted to Robert Hershberg with an exercise price of $4.48 are expected to vest in full on the first anniversary of the grant date (November 5, 2025).

Key Dates

Keywords

Atai Beckley, ATAI, Robert Hershberg, Stock Options, Insider Transaction, SEC Form 4, Beckley Psytech, Acquisition, Director Compensation